首頁 > 市場調查報告書 > 醫療設備

生技設備

次世代定序在臨床腫瘤學中的市場規模、佔有率和成長分析（按技術、工作流程、應用、最終用途和地區分類）—2026-2033年產業預測

市場調查報告書

商品編碼

1896837

次世代定序在臨床腫瘤學中的市場規模、佔有率和成長分析（按技術、工作流程、應用、最終用途和地區分類）—2026-2033年產業預測

Clinical Oncology Next Generation Sequencing Market Size, Share, and Growth Analysis, By Technology, By Workflow, By Application, By End-use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月17日 | 出版商:

SkyQuest | 英文 242 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球次世代定序市場規模預計在 2024 年達到 4.4042 億美元，從 2025 年的 5.1045 億美元成長到 2033 年的 16.6195 億美元，在預測期（2026-2033 年）內複合年成長率為 15.9%。

次世代定序(NGS) 技術透過實現全基因組的快速、擴充性定序，徹底革新了臨床腫瘤學，顯著改善了個人化癌症治療策略。該技術有助於識別新型和罕見的癌症突變，檢測家族內的遺傳突變，並為最佳化標靶治療提供重要的遺傳資訊。 NGS 工作流程的關鍵環節是 DNA 預處理，它為精確定序準備樣本。此外，先進的平台能夠分析原始 NGS 數據，使醫學專家能夠結合實驗性和已通過核准的療法來評估基因組突變。因此，NGS 數據處理系統對於確保針對不同基因型患者及其相應的藥物反應提供更有效的治療方案，以及實現個體化腫瘤治療至關重要。

推動全球臨床腫瘤學次世代定序市場發展的因素

全球臨床腫瘤學次世代定序市場正經歷顯著成長，這主要得益於幾個關鍵因素。對能夠進行次世代定序(NGS) 的先進技術的需求不斷成長，這與人們對個人化醫療和伴隨診斷檢測日益成長的興趣相契合。此外，NGS 在液態生物檢體的應用不斷擴展，預計將為該行業帶來可觀的收入。這種創新方法能夠對循環腫瘤 DNA 進行定序，從而實現非侵入性、即時的癌症分析和監測。此外，腫瘤學研究經費的增加也促進了全球臨床腫瘤學 NGS 解決方案市場的擴張。

限制全球臨床腫瘤學次世代定序市場發展的因素

由於這些先進診斷流程高成本，全球臨床腫瘤學次世代定序市場面臨嚴峻挑戰。世界各地的患者都面臨臨床腫瘤定序的高昂費用，這給醫療系統帶來了巨大的壓力，迫使其證明這些支出的合理性。在許多地區，政治不穩定和經濟困難引發了人們對公共醫療資金永續性的擔憂。這種情況在低收入國家尤其嚴重，缺乏負擔得起的癌症治療對公眾健康和預期壽命產生了負面影響。此外，治療罕見癌症所需的耗材和專用設備的高昂價格也進一步阻礙了市場成長。

全球臨床腫瘤學次世代定序市場趨勢

全球臨床腫瘤學次世代定序(NGS) 市場正經歷著重大的模式轉移，主要得益於 NGS 在液態生物檢體應用中日益廣泛的應用。這項創新技術能夠對循環腫瘤 DNA定序，從而實現對癌症進展的非侵入性即時監測。憑藉其同時定序多個基因組的先進能力，NGS 技術正逐漸成為癌症診斷的基礎。其速度快、靈敏度高、成本效益高等固有優勢正推動 NGS 在臨床領域的應用，許多檢查室已將其納入常規診斷流程。因此，這一趨勢預計將推動市場成長，並重新定義癌症治療策略。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Illumina, Inc.（US）
Thermo Fisher Scientific, Inc.（US）
F. Hoffmann-La Roche AG（Switzerland）
Qiagen NV（Netherlands）
Agilent Technologies, Inc.（US）
BGI Genomics Co., Ltd.（China）
PerkinElmer, Inc.（US）
Oxford Nanopore Technologies, Inc.（UK）
Pacific Biosciences of California, Inc.（US）
Eurofins Scientific SE（Luxembourg）
Myriad Genetics, Inc.（US）
Guardant Health, Inc.（US）
Natera, Inc.（US）
Biocartis Group NV（Belgium）

結論與建議

簡介目錄

Product Code: SQMIG35H2071

Global Clinical Oncology Next Generation Sequencing Market size was valued at USD 440.42 Million in 2024 and is poised to grow from USD 510.45 Million in 2025 to USD 1661.95 Million by 2033, growing at a CAGR of 15.9% during the forecast period (2026-2033).

Next-generation sequencing (NGS) has revolutionized clinical oncology by enabling rapid and scalable sequencing of entire genomes, markedly enhancing personalized cancer treatment strategies. This technology allows for the identification of novel and rare cancer mutations, facilitates the detection of hereditary mutations in family members, and provides essential genetic insights to optimize targeted therapies. A critical component of the NGS workflow is DNA pre-sequencing, which prepares samples for accurate sequencing. Furthermore, advanced platforms analyze raw NGS data, empowering healthcare professionals to assess genomic alterations in conjunction with experimental and approved therapies. Consequently, NGS data processing systems are increasingly pivotal for delivering tailored oncology care, ensuring more effective treatment options for diverse patient genotypes and their corresponding drug responses.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Clinical Oncology Next Generation Sequencing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Clinical Oncology Next Generation Sequencing Market Segments Analysis

Global Clinical Oncology Next Generation Sequencing Market is segmented by Technology, Workflow, Application, End-use and region. Based on Technology, the market is segmented into Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing. Based on Workflow, the market is segmented into NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis. Based on Application, the market is segmented into Screening, Sporadic Cancer, Inherited Cancer, Companion Diagnostics and Other Diagnostics. Based on End-use, the market is segmented into Hospitals, Clinics and Laboratories. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Clinical Oncology Next Generation Sequencing Market

The Global Clinical Oncology Next Generation Sequencing market is experiencing significant growth driven by several key factors. The rising demand for advanced technologies capable of performing next-generation sequencing (NGS) aligns with the increasing interest in personalized medicine and diagnostic companion tests. Furthermore, enhancing the application of NGS for liquid biopsies is expected to generate substantial revenue within the industry. This innovative approach allows for the sequencing of circulating tumor DNA, enabling non-invasive real-time cancer profiling and monitoring. Additionally, an increase in funding for oncology research contributes to the expansion of the global market for clinical oncology NGS solutions.

Restraints in the Global Clinical Oncology Next Generation Sequencing Market

The Global Clinical Oncology Next Generation Sequencing market faces significant challenges due to the high costs associated with these advanced diagnostic processes. Patients worldwide grapple with the prohibitive expenses of clinical oncology sequencing, which places immense pressure on healthcare systems to justify these costs. In many regions, political instability and economic difficulties are raising concerns about the sustainability of public healthcare funding. This situation is particularly dire in countries with low income levels, where the lack of affordable cancer treatments adversely affects overall public health and life expectancy. Furthermore, the steep prices of essential consumables and specialized equipment for rare cancer treatments further hinder market growth.

Market Trends of the Global Clinical Oncology Next Generation Sequencing Market

The Global Clinical Oncology Next Generation Sequencing (NGS) market is witnessing a significant paradigm shift, driven by the increasing implementation of NGS in liquid biopsy applications. This innovation enables the sequencing of circulating tumor DNA, facilitating non-invasive and real-time monitoring of cancer progression. With advanced capabilities that allow simultaneous sequencing of multiple genomes, NGS technology is becoming a cornerstone in cancer diagnostics. Its inherent advantages-speed, sensitivity, and cost-effectiveness-are propelling its adoption in clinical settings, and many laboratories are transitioning to routine diagnostic applications. Consequently, this trend is poised to enhance market growth and redefine cancer treatment strategies.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Study Analysis

Global Clinical Oncology Next Generation Sequencing Market Size by Technology & CAGR (2026-2033)

Market Overview
Whole Genome Sequencing
Whole Exome Sequencing
Targeted Sequencing & Resequencing

Global Clinical Oncology Next Generation Sequencing Market Size by Workflow & CAGR (2026-2033)

Market Overview
NGS Pre-Sequencing
NGS Sequencing
NGS Data Analysis

Global Clinical Oncology Next Generation Sequencing Market Size by Application & CAGR (2026-2033)

Market Overview
Screening
Sporadic Cancer
Inherited Cancer
Companion Diagnostics
Other Diagnostics

Global Clinical Oncology Next Generation Sequencing Market Size by End-use & CAGR (2026-2033)

Market Overview
Hospitals
Clinics
Laboratories

Global Clinical Oncology Next Generation Sequencing Market Size & CAGR (2026-2033)

North America (Technology, Workflow, Application, End-use)
- US
- Canada
Europe (Technology, Workflow, Application, End-use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Technology, Workflow, Application, End-use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Technology, Workflow, Application, End-use)
- Brazil
- Rest of Latin America
Middle East & Africa (Technology, Workflow, Application, End-use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Qiagen N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BGI Genomics Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oxford Nanopore Technologies, Inc. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pacific Biosciences of California, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eurofins Scientific SE (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocartis Group NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments